Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 16/20 | 0.55 |
| ▸ | CCR2 | P41597 | 2/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 14/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848549 | 0.83 | CCR2 (0.50) | ADRA1ACCR2ADRA1BADRA1DHRH1 | |
| SCHEMBL6646061 | 0.78 | CCR2 (0.42) | ADRA1ACCR2 | |
| SCHEMBL6222128 | 0.73 | DRD2 (0.66) | — | |
| SCHEMBL21068738 | 0.73 | TP53 (0.44) | ADRA1AADRA1BADRA1D | |
| SCHEMBL7063425 | 0.72 | ADRA1D (0.47) | ADRA1ACCR2ADRA1BADRA1D | |
| SCHEMBL25404049 | 0.72 | CCR3 (0.62) | HRH1 | |
| SCHEMBL21815092 | 0.71 | GNAI3 (0.46) | ADRA1AADRA1BADRA1D | |
| SCHEMBL14587471 | 0.71 | ADRA1D (0.63) | ADRA1AADRA1BADRA1D | |
| SCHEMBL7067307 | 0.69 | DRD2 (0.60) | ADRA1ACCR2ADRA1BADRA1D | |
| SCHEMBL27234242 | 0.69 | TP53 (0.41) | ADRA1AADRA1BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 88/4885CCR2 470/4885ADRA1B 143/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 224/4885CCR2 513/4885ADRA1B 306/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1A 161/4885CCR2 420/4885ADRA1B 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.